Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study

E. Daudén; Christopher Em Griffiths; Ortonne Jp; Knud Kragballe; CT Molta; Deborah Robertson; Ronald Pedersen; Joanne Estojak; R. Boggs

doi:10.1111/j.1468-3083.2009.03321.x

Shared by

Christopher Em Griffiths

Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study

Article 2009 en

Authors

ED
E. Daudén
Christopher Em Griffiths
OJ
Ortonne Jp

Abstract

1 min read

At baseline, patients exhibited significant quality-of-life impairment. Both continuous and paused etanercept treatment provided improvements in PRO measures. Either regimen could be considered and care should be individualized.

Related publications

Article2008

Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to-severe psoriasis over 54 weeks: the CRYSTEL study

Jean‐Paul Ortonne, Christopher Em Griffiths, E. Daudén, Robert Strohal, Deborah Robertson, Ronald Pedersen, C. Molta, Bruce Freundlich

Article2016

Effect of tofacitinib withdrawal and re‐treatment on patient‐reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis

Christopher Em Griffiths, Ronald Vender, Howard Sofen, Leon Kircik, Huaming Tan, Scott T. Rottinghaus, Mary Bachinsky, Lotus Mallbris, Carla Mamolo

Article2010

Definition of treatment goals for moderate to severe psoriasis: a European consensus

Ulrich Mrowietz, Knud Kragballe, Kristian Reich, Phyllis I. Spuls, Christopher Em Griffiths, Alexander Nast, J Franke, C. Antoniou, Petr Arenberger, Flora Balieva, Matilda Bylaitė, Osvaldo Correia, E. Daudén, Paolo Gisondi, Lars Iversen, Lajos Kemény, M. Lahfa, Tamar Nijsten, Tapio Rantanen, Adam Reich, T. Rosenbach, Siegfried Segaert, Catherine Smith, T. Talme,

Article2022

Patient reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after imatinib treatment in INTRIGUE: A phase 3 open-label study.

Hans Gelderblom, Robin L. Jones, Jean Yves Blay, Suzanne George, Patrick Schöffski, Margaret von Mehren, John Zalcberg, Yoon‐Koo Kang, Albiruni Ryan Abdul Razak, Jonathan C. Trent, Steven Attia, Axel Le Cesne, B. Harrow, Claus Becker, Tao Wang, Matthew L. Sherman, Rodrigo Ruiz‐Soto, Michael C. Heinrich, Sebastian Bauer

Article2023

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Absolute PASI Outcomes Over 52 Weeks in the Phase 3 POETYK PSO-1 Trial

Mark Lebwohl, Melinda Gooderham, Richard B. Warren, Diamant Thaçi, Peter Foley, Alice B. Gottlieb, Lauren Hippeli, Renata M. Kisa, Subhashis Banerjee, Christopher Em Griffiths